Entity > Corporation > US > New York City New York > Inhibrx

About Inhibrx

Inhibrx, Inc. is a clinical-stage biotechnology company dedicated to helping people with life-threatening diseases through scientific innovation and excellence. Inhibrx, Inc. employs various protein engineering methods to address the specific needs of complex targets and diseases, including its proprietary sdAb platform.

The Proprietary Sdab Platform From Inhibrx, Inc: Our proprietary sdAb platform enables us to address complex target biology where other biological approaches have failed or are suboptimal. Our precision engineering enables the generation of therapeutic candidates with defined valences and specificities that we believe can lead to optimal mechanisms of action.

Currently, Four Inhibrx, Inc. Programs Are In Ongoing Clinical Trials: Drawing on the breadth and depth of our team's experience and capabilities, and using our proprietary technology, we have developed a promising pipeline that we believe has properties and mechanisms of action superior to existing approaches in the field. Three programs target the treatment of various cancers and one targets alpha-1 antitrypsin deficiency (AATD). In addition, INBRX-121 is our newest preclinical program currently in cell line development.

Inhibrx, Inc. And Bluebird Bio Began A Research Collaboration In 2016: Since then, the collaboration has focused on the discovery, development and commercialization of chimeric antigen receptor (CAR) T-cell therapies using Inhibrx's proprietary single-domain antibody (sdAb) platform for multiple cancer targets.

The Formation And Headquarters Of Inhibrx, Inc: Inhibrx was founded in 2010 and is currently headquartered in La Jolla, California, USA.

The Mission Of Inhibrx, Inc. Is To Provide Optimized Biologic Therapeutics To People With Life-Threatening Diseases: To achieve this goal, we have built a large and diverse pipeline that has the potential to impact cancer and rare diseases through our single-domain antibody platform technology. Single-domain antibodies (sdAbs) provide a small, simple, modular target binding domain that can be combined in multiple ways to meet the specific needs of unique biological targets.

Industry: Business & Industrial > Pharmaceuticals & Biotech

More information about Inhibrx

Company Attribute Value
Address StreetAddress: 11025 N Torrey Pines Rd Ste 200, AddressLocality: La Jolla, AddressRegion: California, PostalCode: 92037, AddressCountry: United States
Founding Date 2011
Name Inhibrx
Number Of Employees 106
Revenue $7,271,000 USD
Ticker Symbol NASDAQ: INBX
Url inhibrx
Linkedin linkedin
Google google
Wikidata wikidata



New York City, US
23 Sep 2023

New York City, US
23 Sep 2023


Page: 1 Desktop | Laptop Devices
Inhibrx | Discover our clinical-stage biotechnology company.
Our team members possess deep scientific and clinical experience in discovering and developing protein therapeutics. With the flexibility and spirit of a start- ... › company › inhibrx
Inhibrx, Inc.
At Inhibrx, our mission is to deliver optimized, biologic therapeutics to people with life-threatening conditions. Toward this goal, we have built a large ... › news-releases
Inhibrx | Investors - News Releases
Inhibrx Announces $200 Million Private Placement Financing. Aug 7, 2023. Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights. › news-releases › inhibrx...
Inhibrx Announces $200 Million Private Placement Financing
Aug 29, 2023 — Inhibrx is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates in ... › quote › INBX
Inhibrx, Inc. (INBX) Stock Price, News, Quote & History
(Nasdaq: INBX) ("Inhibrx" or the "Company"), a biopharmaceutical company with four clinical programs in development and a strong emerging pipeline, today ... › Archives › edgar › data › inhibrx-...
Inhibrx, Inc., or the Company, or Inhibrx, is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic ... › quote › INBX:US
INBX: Inhibrx Inc Stock Price Quote - NASDAQ GM
offers biologic therapeutics for people with life-threatening conditions. The Company focuses on developing a diverse pipeline of therapeutic candidates. › symbol › INBX
Inhibrx, Inc. (INBX) Stock Price, Quote, News & Analysis
Inhibrx, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel biologic therapeutic candidates.
Related Searches
Related Searches
Inhibrx products
inhibrx address
Inhibrx stock
Knowledge Panel
Knowledge Panel

Inhibrx (Biotechnology company)

  • Stock price : INBX (NASDAQ) $19.48 -0.04 (-0.20%)Sep 22, 4:00 PM EDT - Disclaimer
  • Headquarters : La Jolla, CA
  • Founded : 2010
  • Subsidiary : Inbrx 103, LLC

Related Entities Inhibrx

Entity Home Kalicube Pro Entity Page
Inhibrx Entity Home Inhibrx on Kalicube

All information on this page is taken from publicly available sources, and the analysis we provide is a representation of Google's search results for the entity and does not represent any opinion or judgement about the entity by Kalicube itself. If you disagree with this analysis, please contact us and cite this reference : 193787